Assessing the stability of polio eradication after the withdrawal of oral polio vaccine
暂无分享,去创建一个
Michael Famulare | Guillaume Chabot-Couture | Kevin A McCarthy | P. Eckhoff | G. Chabot-Couture | C. Selinger | M. Famulare | Christian Selinger | K. McCarthy | Philip A Eckhoff
[1] R. Sutter,et al. 49 – Poliovirus Vaccine–Live , 2018 .
[2] M. Rennels,et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. , 2005, The Journal of infectious diseases.
[3] W. P. Glezen,et al. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. , 1969, American journal of epidemiology.
[4] A A Tsiatis,et al. Human infective dose determinations for oral poliovirus type 1 vaccine in infants , 1981, Journal of clinical microbiology.
[5] John Tj,et al. Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status , 2013 .
[6] G. Dick,et al. Vaccination Against Poliomyelitis with Live Virus Vaccines—8 , 1961, British medical journal.
[7] M. Pallansch,et al. Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination , 2015, BMC Infectious Diseases.
[8] E. C. Beuvery,et al. Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus. , 1999, Vaccine.
[9] J. Fox,et al. Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. , 1959, Journal of the American Medical Association.
[10] V. Agol,et al. Retrospective Analysis of a Local Cessation of Vaccination against Poliomyelitis: a Possible Scenario for the Future , 2003, Journal of Virology.
[11] J. Whalen,et al. Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. , 1961, Pediatrics.
[12] N Woodford,et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[13] R. Bassal,et al. Field study of fecal excretion as a decision support tool in response to silent reintroduction of wild-type poliovirus 1 into Israel. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[14] B. Hersh,et al. Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988-1995. , 1997, The Journal of infectious diseases.
[15] M. Zemlin,et al. Ontogeny of the intestinal immune system , 2009 .
[16] J. S. Reeves,et al. Immunization of infants with the Sabin oral poliovirus vaccine. , 1962, American journal of public health and the nation's health.
[17] R. Andino,et al. Rationalizing the development of live attenuated virus vaccines , 2010, Nature Biotechnology.
[18] Epidemiology Subcommittee. Evaluation of Sabin live poliovirus vaccine in Japan. II. Clinical, virologic and immunologic effects of vaccine in children. , 1966, Japanese journal of medical science & biology.
[19] N. Grassly,et al. Efficacy of inactivated poliovirus vaccine in India , 2014, Science.
[20] S. Cochi,et al. Contribution of Global Polio Eradication Initiative–Funded Personnel to the Strengthening of Routine Immunization Programs in the 10 Focus Countries of the Polio Eradication and Endgame Strategic Plan , 2017, The Journal of infectious diseases.
[21] M. Pallansch,et al. Assessing population immunity in a persistently high-risk area for wild poliovirus transmission in India: a serological study in Moradabad, Western Uttar Pradesh. , 2014, The Journal of infectious diseases.
[22] M. Pallansch,et al. Expert Review on Poliovirus Immunity and Transmission , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[23] J. Fox,et al. Observations on natural poliovirus infections in immunized children. , 1957, American Journal of Public Health and the Nations Health.
[24] Y. Manor,et al. Insidious reintroduction of wild poliovirus into Israel, 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[25] Philip A. Eckhoff,et al. Quantifying the Impact of Expanded Age Group Campaigns for Polio Eradication , 2014, PloS one.
[26] A. Sasaki,et al. Estimating the Risk of Re-Emergence after Stopping Polio Vaccination , 2012, Front. Microbio..
[27] M. Kretzschmar,et al. Linking the seroresponse to infection to within-host heterogeneity in antibody production. , 2016, Epidemics.
[28] R. Sutter,et al. Update on Vaccine-Derived Polioviruses — Worldwide, January 2017–June 2018 , 2016, MMWR. Morbidity and mortality weekly report.
[29] Manfred S. Green,et al. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. , 2008, Vaccine.
[30] Hil M. Lyons,et al. Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates. , 2017, Vaccine.
[31] A. E. Casey. THE INCUBATION PERIOD IN EPIDEMIC POLIOMYELITIS , 1942 .
[32] R B Cairns,et al. Friendships and social networks in childhood and adolescence: fluidity, reliability, and interrelations. , 1995, Child development.
[33] A. Beale,et al. A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine , 1966, Journal of Hygiene.
[34] M. Famulare. Has Wild Poliovirus Been Eliminated from Nigeria? , 2015, PloS one.
[35] Roland W Sutter,et al. The new polio eradication end game: rationale and supporting evidence. , 2014, The Journal of infectious diseases.
[36] N. Nathanson,et al. From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed , 2010, American journal of epidemiology.
[37] E. Wimmer,et al. Vaccination against polio should not be stopped , 2007, Nature Reviews Microbiology.
[38] R. Sutter,et al. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. , 2014, The Journal of infectious diseases.
[39] M. Pallansch,et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. , 2005, Annual review of microbiology.
[40] Linda J S Allen,et al. Probability of a Disease Outbreak in Stochastic Multipatch Epidemic Models , 2013, Bulletin of mathematical biology.
[41] Stewart T. Chang,et al. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria , 2015, Journal of Virology.
[42] R. Sutter,et al. Outbreaks of paralytic poliomyelitis, 1976-1995. , 1997, The Journal of infectious diseases.
[43] M. L. Yakovenko,et al. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus , 2016, Journal of Virology.
[44] M. Pallansch,et al. Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine‐Derived Polioviruses (cVDPVs) , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[45] G. Dick,et al. Vaccination Against Poliomyelitis with Live Virus Vaccines—6* , 1961, British medical journal.
[46] T. Chin,et al. Immunity induced by inactivated poliovirus vaccine and excretion of virus. , 1984, Reviews of infectious diseases.
[47] N. Grassly,et al. Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.
[48] P. Strebel,et al. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994. , 1997, The Journal of infectious diseases.
[49] J. Meredith,et al. Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication , 2006, Journal of Virology.
[50] N. Grassly,et al. An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia , 2017, BMC Infectious Diseases.
[51] D. Heymann,et al. A global call for new polio vaccines , 2005, Nature.
[52] Joel C Miller,et al. Model hierarchies in edge-based compartmental modeling for infectious disease spread , 2013, Journal of mathematical biology.
[53] A. V. van Loon,et al. Poliomyelitis in the Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992 , 1995, Epidemiology and Infection.
[54] I. Dömök,et al. Virus Excretion after Mass Vaccination with Attenuated Polioviruses in Hungary , 1961, British medical journal.
[55] N. Grassly,et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. , 2009, The Journal of infectious diseases.
[56] R. Price,et al. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens , 2015, BMC Infectious Diseases.
[57] N. Grassly,et al. Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. , 2010, The Journal of infectious diseases.
[58] W. J. Liu,et al. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). , 1986, Bulletin of the World Health Organization.
[59] F. de Fraipont,et al. Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on vero cells or on primary monkey kidney cells , 1997, Journal of medical virology.
[60] Karima R. Nigmatulina,et al. A quantitative survey of the literature on poliovirus infection and immunity. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[61] Y. Manor,et al. Laboratory challenges in response to silent introduction and sustained transmission of wild poliovirus type 1 in Israel during 2013. , 2014, The Journal of infectious diseases.
[62] C Kelly,et al. BULLETIN EUROPÉEN SUR LES MALADIES TRANSMISSIBLES / EUROPEAN COMMUNICABLE DISEASE BULLETIN , 2003 .
[63] F. Braka,et al. Continued Endemic Wild Poliovirus Transmission in Security-Compromised Areas — Nigeria, 2016 , 2017, MMWR. Morbidity and mortality weekly report.
[64] Kimberly M Thompson,et al. Modeling Poliovirus Risks and the Legacy of Polio Eradication , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[65] M. Pallansch,et al. Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[66] Thomas D. Snyder,et al. 120 Years of American Education: A Statistical Portrait. , 1993 .
[67] K. Thompson,et al. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.
[68] L. Hampton,et al. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. , 2016, MMWR. Morbidity and mortality weekly report.
[69] T. Kimman,et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. , 1999, Journal of immunology.
[70] V. Vashishtha,et al. Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status , 2013, The Indian journal of medical research.
[71] M. Pallansch,et al. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. , 1997, The Journal of infectious diseases.
[72] D. Kromhout,et al. Circulation of poliovirus during the poliomyelitis outbreak in The Netherlands in 1992-1993. , 1996, American journal of epidemiology.
[73] T. Pollock,et al. Vaccination of Adults with a British Oral Poliomyelitis Vaccine Prepared from Sabin Strains , 1961, British medical journal.
[74] K. Thompson,et al. Modeling the dynamics of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.
[75] M. Mulders,et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93 , 1994, The Lancet.
[76] Qi Chen,et al. Multiple Independent Emergences of Type 2 Vaccine-Derived Polioviruses during a Large Outbreak in Northern Nigeria , 2013, Journal of Virology.
[77] D. Purdie,et al. Immunoglobulins in saliva of preterm and full-term infants. , 2003, Oral microbiology and immunology.
[78] R. Pebody. Polio vaccination in Europe: the shift from OPV to IPV use , 2004 .
[79] W A Furumoto,et al. A mathematical model for the infectivity-dilution curve of tobacco mosaic virus: theoretical considerations. , 1967, Virology.
[80] D. S. Dane,et al. Vaccination Against Poliomyelitis with Live Virus Vaccines—7 , 1961, British medical journal.
[81] M. Pallansch,et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. , 2015, The Journal of infectious diseases.
[82] Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. , 2011, MMWR. Morbidity and mortality weekly report.
[83] Joel C. Miller,et al. Epidemic Percolation Networks, Epidemic Outcomes, and Interventions , 2011, Interdisciplinary perspectives on infectious diseases.
[84] I. Onorato,et al. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. , 1991, The Journal of infectious diseases.
[85] J. Schijven,et al. Risk assessment, risk management and risk-based monitoring following a reported accidental release of poliovirus in Belgium, September to November 2014. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[86] Dong Dx,et al. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). , 1988 .
[87] S. Plotkin,et al. 27 – Poliovirus vaccine—inactivated , 2013 .
[88] R. D. Tebbens,et al. Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[89] J. Dushoff,et al. The effects of population heterogeneity on disease invasion. , 1995, Mathematical biosciences.
[90] M. Chumakov. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. , 1961, Bulletin of the World Health Organization.
[91] R. Mikolajczyk,et al. Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases , 2008, PLoS medicine.
[92] M. L. Yakovenko,et al. Spread of Vaccine-Derived Poliovirus from a Paralytic Case in an Immunodeficient Child: an Insight into the Natural Evolution of Oral Polio Vaccine , 2005, Journal of Virology.
[93] A. Sabin. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. , 1985, The Journal of infectious diseases.
[94] A. Paul,et al. Chemical Synthesis of Poliovirus cDNA: Generation of Infectious Virus in the Absence of Natural Template , 2002, Science.
[95] Enrique Beldarraín. Poliomyelitis and its elimination in Cuba: an historical overview. , 2013, MEDICC review.
[96] S. Self,et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. , 2015, The Lancet. Infectious diseases.
[97] A. Sabin,et al. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. , 1960 .
[98] Chumakov Mp. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. , 1961 .
[99] P. Wright,et al. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. , 1991, Reviews of infectious diseases.
[100] W. Weldon,et al. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. , 2015, Vaccine.
[101] Walter A Orenstein,et al. Polio vaccination: past, present and future. , 2015, Future microbiology.
[102] R. Sutter,et al. Poliovirus vaccine-live , 2008 .
[103] Michael Famulare,et al. The risk of type 2 oral polio vaccine use in post-cessation outbreak response , 2017, BMC Medicine.
[104] F. Shuaib,et al. Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission, Nigeria, 2016. , 2016, Releve epidemiologique hebdomadaire.
[105] Y. Manor,et al. Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[106] Z. Grossman,et al. Resolution of the Pathways of Poliovirus Type 1 Transmission during an Outbreak , 2000, Journal of Clinical Microbiology.
[107] R. Sutter,et al. Progress Toward Containment of Poliovirus Type 2 — Worldwide, 2017 , 2017, MMWR. Morbidity and mortality weekly report.
[108] P E Fine,et al. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. , 1999, American journal of epidemiology.
[109] K. Thompson,et al. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use , 2016, BMC Infectious Diseases.
[110] M. Pallansch,et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. , 2004, JAMA.
[111] R. Sutter,et al. Mass vaccination campaigns for polio eradication: an essential strategy for success. , 2006, Current topics in microbiology and immunology.
[112] E. Opton,et al. Immunization of preschool children with oral poliovirus vaccine (Sabin). , 1961, JAMA.
[113] E. Hossny,et al. Monovalent type 1 oral poliovirus vaccine in newborns. , 2008, The New England journal of medicine.
[114] Cynthia B. Snider,et al. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. , 2014, Vaccine.
[115] F. Shuaib,et al. Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016. , 2016, MMWR. Morbidity and mortality weekly report.
[116] S. Self,et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial , 2016, The Lancet.
[117] Miguel A. Galindo,et al. Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba , 2007 .
[118] Volume Forty Seven. HEALTH AND DEMOGRAPHIC SURVEILLANCE SYSTEM - MATLAB , 2015 .
[119] J. Fox,et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. , 1957, American journal of hygiene.
[120] H. Larson,et al. Listening to the rumours: What the northern Nigeria polio vaccine boycott can tell us ten years on , 2013, Global public health.
[121] Joel C. Miller,et al. A Note on the Derivation of Epidemic Final Sizes , 2012, Bulletin of mathematical biology.
[122] G. Kang,et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial , 2014, The Lancet.
[123] M. Pallansch,et al. Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine‐Related Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[124] T. Chin,et al. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. , 1962, American journal of hygiene.
[125] Continued endemic wild poliovirus transmission in security-compromised areas – Nigeria, 2016. , 2017, Releve epidemiologique hebdomadaire.
[126] Christophe Fraser,et al. New Strategies for the Elimination of Polio from India , 2006, Science.
[127] P. Rohani,et al. Modeling Infectious Diseases , 2020, Strad Research.
[128] Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. , 2003, The Indian journal of medical research.
[129] Y. Manor,et al. Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel , 2016, BMC Medicine.
[130] S. Matsui,et al. Host and Viral Factors Affecting the Decreased Immunogenicity of Sabin Type 3 Vaccine after Administration of Trivalent Oral Polio Vaccine to Rural Mayan Children , 1997, The Journal of infectious diseases.
[131] J. P. Davis,et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. , 2009, The Journal of infectious diseases.
[132] A. V. van Loon,et al. Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in The Netherlands. , 2001, The Journal of infectious diseases.
[133] M. J. Uddin,et al. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study , 2017, The Lancet. Infectious diseases.
[134] O. Diop,et al. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 — Worldwide, 2016–2017 , 2017, MMWR. Morbidity and mortality weekly report.
[135] W. P. Glezen,et al. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. , 1966, American journal of epidemiology.
[136] Illiam,et al. THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.
[137] Chris Wolff,et al. Containment of Polioviruses After Eradication and OPV Cessation: Characterizing Risks to Improve Management , 2006, Risk analysis : an official publication of the Society for Risk Analysis.
[138] T. Kimman,et al. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. , 2005, The Journal of infectious diseases.
[139] J. Melnick,et al. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. , 1967, American journal of epidemiology.